title: Adalimumab-Induced Cutaneous Lupus Erythematosus in a 16-Year-Old Girl with Juvenile Idiopathic Arthritis.
abstract: Tumor necrosis factor α (TNF-α) antagonists are used in the treatment of numerous autoimmune conditions. Adalimumab is the first monoclonal antibody to TNF-α and is used to treat juvenile idiopathic arthritis. A growing body of literature associates anti-TNF-α therapies with several adverse dermatologic manifestations, including drug-induced lupus erythematosus (LE). We describe a case of cutaneous LE in a 16-year-old girl treated with adalimumab for juvenile idiopathic arthritis. The temporal association between her presenting symptoms and adalimumab initiation and gradual improvement after stopping biologic therapy suggest adalimumab-induced cutaneous LE. With increasing use of anti-TNF therapies in children, the potential for drug-induced LE should not be overlooked.
authors.affiliation: College of Physicians and Surgeons, Columbia University, New York, New York.|University of California at San Francisco Benioff Children's Hospital Oakland, Oakland, California.
authors.forename: Emily S
authors.initials: ES
authors.lastname: West
authors.affiliation: Division of Rheumatology, Department of Pediatrics, Seattle Children's Hospital, University of Washington, School of Medicine, Seattle, Washington.
authors.forename: Kabita
authors.initials: K
authors.lastname: Nanda
authors.affiliation: Division of Dermatology, Department of Medicine, University of Washington, School of Medicine, Seattle, Washington.
authors.forename: Ope
authors.initials: O
authors.lastname: Ofodile
authors.affiliation: Department of Pathology, Seattle Children's Hospital, University of Washington, School of Medicine, Seattle, Washington.
authors.forename: Joe
authors.initials: J
authors.lastname: Rutledge
authors.affiliation: Division of Dermatology, Department of Pediatrics, Seattle Children's Hospital, University of Washington, School of Medicine, Seattle, Washington.
authors.forename: Heather A
authors.initials: HA
authors.lastname: Brandling-Bennett
mesh_terms: D000068879:Adalimumab / Q000009:adverse effects*; D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D001706:Biopsy; D005260:Female; D006801:Humans; D008178:Lupus Erythematosus, Cutaneous / Q000139:chemically induced* / Q000473:pathology; D012867:Skin / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000893:Anti-Inflammatory Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab